ImmunoCellular Therapeutics Ltd
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company's lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokin… Read more
Market Cap & Net Worth: ImmunoCellular Therapeutics Ltd (IMUC)
ImmunoCellular Therapeutics Ltd (PINK:IMUC) has a market capitalization of $19.48 Million ($19.48 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #36335 globally and #11823 in its home market, demonstrating a -0.65% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ImmunoCellular Therapeutics Ltd's stock price $0.15 by its total outstanding shares 126502860 (126.50 Million).
ImmunoCellular Therapeutics Ltd Market Cap History: 2015 to 2025
ImmunoCellular Therapeutics Ltd's market capitalization history from 2015 to 2025. Data shows change from $17.98 Billion to $19.48 Million (-52.36% CAGR).
ImmunoCellular Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ImmunoCellular Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of IMUC by Market Capitalization
Companies near ImmunoCellular Therapeutics Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to ImmunoCellular Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ImmunoCellular Therapeutics Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, ImmunoCellular Therapeutics Ltd's market cap moved from $17.98 Billion to $ 19.48 Million, with a yearly change of -52.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $19.48 Million | -9.41% |
| 2024 | $21.51 Million | -26.72% |
| 2023 | $29.35 Million | -71.70% |
| 2022 | $103.69 Million | +95.17% |
| 2021 | $53.13 Million | +2.44% |
| 2020 | $51.87 Million | +19.88% |
| 2019 | $43.26 Million | +101.18% |
| 2018 | $21.51 Million | -94.62% |
| 2017 | $399.75 Million | -84.59% |
| 2016 | $2.59 Billion | -85.58% |
| 2015 | $17.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ImmunoCellular Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.48 Million USD |
| MoneyControl | $19.48 Million USD |
| MarketWatch | $19.48 Million USD |
| marketcap.company | $19.48 Million USD |
| Reuters | $19.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.